Previous 10 | Next 10 |
home / stock / wxxwy / wxxwy news
WuXi Biologics (WXXWY) will acquire biologics manufacturing facilities in Hangzhou, China, from Pfizer China (PFE) in a deal expected to close in the first half of the year.Financial details were not disclosed.WuXi says the acquisition of the 50,000 square-meter facilities will allow the comp...
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private investments. These companies are ripe for significant growth, at the same time, BM...
In a positive start to 2021, the representative ETFs of Chinese companies rallied by a wide margin over with their respective U.S. counterparts. The outperformance came despite the dark cloud of investment bans on Alibaba and Tencent, as well as usage prohibition of certain Chine...
Jacobio raised $174 million in a Hong Kong IPO to develop its portfolio of 12 novel drugs. WuXi Biologics will add more CDMO capacity by spending $183 million to acquire a Bayer facility in Germany. CASI Pharma announced its partnered CD19 CAR-T product was granted Breakthrough De...
Wuxi Biologics (WXXWY) is acquiring a drug substance facility from Bayer (BAYZF) to ramp up its global supply network of COVID-19 vaccines and other biologics.As part of the agreement, the two companies also plan to enter a long-term sublease agreement and a transition service contr...
Arcus Biosciences ([[RCUS]] +2.6%) has expanded its existing strategic relationship with WuXi Biologics ([[WXXWY]] -65.6%) to discover anti-CD39 antibodies using the latter’s proprietary technology. It is the fourth antibody development program for which the two firms have collabo...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (SREs) in patients with bone metastases from solid tumors or multiple myeloma. LianBio, a P...
In the US, a comparison of the MSCI USA and MSCI USA ESG indexes shows that ESG did not increase performance with the former returning 140% and the latter 130% since 2013. It is important to note that the ESG criteria MSCI uses for its China ESG indexes are the same criteria MSCI uses...
AC Immune (ACIU) and WuXi Biologics (WXXWY) plan to accelerate advancement of AC Immune’s TDP-43 antibody into clinical development for NeuroOrphan indications. This next phase of the strategic partnership between the companies builds on the know-how of ACIU's drug discovery and develo...
News, Short Squeeze, Breakout and More Instantly...
Wuxi Biologics Cayman Inc ADR Company Name:
WXXWY Stock Symbol:
OTCMKTS Market:
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year PR Newswire SHANGHAI , July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), anno...
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale PR Newswire By leveraging WuXiUP TM , WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing ...
WuXi Biologics Receives AAA MSCI ESG Rating PR Newswire SHANGHAI , Nov. 7, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating ...